The Relationship of Anxiety with Alzheimer’s Disease: A Narrative Review

doi:10.2174/1567205018666210823095603
摘要

背景：人们越来越努力更好地了解阿尔茨海默病 (AD) 的神经精神症状，将其作为症状负担的重要特征以及疾病过程的潜在可改变因素。焦虑是阿尔茨海默病 (AD) 中最常见的神经精神症状之一。越来越多的工作已经出现，以解决 AD 中焦虑的流行病学和生物学相关性。方法：在这里，我们回顾了研究 AD 中焦虑的研究和临床队列中的人类研究。我们专注于与 AD 阶段的患病率、与既定生物标志物的相关性、与 AD 神经病理学和遗传风险因素的关系以及对进展的影响相关的工作。结果：焦虑在早期阶段很突出，并在功能阶段的范围内增加。通过 PET 或脑脊液分析测量的 FDG-PET 和淀粉样蛋白水平的生物标志物关系最强。在神经病理学上，焦虑会随着早期 Braak 阶段的 tau 蛋白病理学而出现。载脂蛋白 E e4 等位基因的存在与所有阶段的焦虑增加有关，尤其是在轻度认知障碍时。焦虑预示着痴呆症所有阶段的进展更快。结论：这项工作表明，焦虑与 AD 之间存在密切的生物学关系，这种关系始于早期并影响功能衰退。因此，我们讨论了未来的工作，以提高我们对这种关系的理解，并测试抗焦虑治疗作为 AD 疾病改善疗法的有效性。
关键词: 焦虑、阿尔茨海默病、神经精神病学、早期、临床前、前驱。
[1] 
Alzheimer’s Association Report. 2020 Alzheimer’s disease facts and figures. Alzheimers Dement  2020; 16(3): 391-460.
[http://dx.doi.org/10.1002/alz.12068] [PMID: 32157811] 
[2] 
Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement  2011; 7(3): 280-92.
[http://dx.doi.org/10.1016/j.jalz.2011.03.003] [PMID: 21514248] 
[3] 
Burhanullah MH, Tschanz JT, Peters ME. Neuropsychiatric symptoms as risk factors for cognitive decline in clinically normal older adults: The cache county study. Am J Geriatr Psychiatry  2020; 28(1): 64-71.
[http://dx.doi.org/10.1016/j.jagp.2019.03.023] [PMID: 31186157] 
[4] 
Geda YE, Roberts RO, Knopman DS, et al. Prevalence of neuropsychiatric symptoms in mild cognitive impairment and normal cognitive aging: Population-based study. Arch Gen Psychiatry  2008; 65(10): 1193-8.
[http://dx.doi.org/10.1001/archpsyc.65.10.1193] [PMID: 18838636
                        
                    ] 
[5] 
Khundakar AA, Thomas AJ. Neuropathology of depression in Alzheimer’s disease: Current knowledge and the potential for new treatments. J Alzheimers Dis  2015; 44(1): 27-41.
[http://dx.doi.org/10.3233/JAD-148003] [PMID: 25208623] 
[6] 
Mortby ME, Burns R, Eramudugolla R, Ismail Z, Anstey KJ. Neuropsychiatric symptoms and cognitive impairment: Understanding the importance of co-morbid symptoms. J Alzheimers Dis  2017; 59(1): 141-53.
[http://dx.doi.org/10.3233/JAD-170050] [PMID: 28598846] 
[7] 
Wise EA, Rosenberg PB, Lyketsos CG, Leoutsakos JM. Time course of neuropsychiatric symptoms and cognitive diagnosis in National Alzheimer’s Coordinating Centers volunteers. Alzheimers Dement (Amst)  2019; 11: 333-9.
[http://dx.doi.org/10.1016/j.dadm.2019.02.006] [PMID: 31024987] 
[8] 
Zhang M, Wang H, Li T, Yu X. Prevalence of neuropsychiatric symptoms across the declining memory continuum: An observational study in a memory clinic setting. Dement Geriatr Cogn Disord Extra  2012; 2: 200-8.
[http://dx.doi.org/10.1159/000338410] [PMID: 22719746] 
[9] 
Jack CR Jr, Bennett DA, Blennow K, et al. Nia-aa research framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement  2018; 14(4): 535-62.
[http://dx.doi.org/10.1016/j.jalz.2018.02.018] [PMID: 29653606] 
[10] 
Reisberg B, Ferris SH, de Leon MJ, Crook T. The global deterioration scale for assessment of primary degenerative dementia. Am J Psychiatry  1982; 139(9): 1136-9.
[http://dx.doi.org/10.1176/ajp.139.9.1136] [PMID: 7114305] 
[11] 
Reisberg B, Franssen E, Sclan S, Kluger A, Ferris SH. Stage specific incidence of potentially remediable behavioral symptoms in aging and Alzheimer disease: a study of 120 patients using the BEHAVE-AD. Bull Clin Neurosci  1989; 54: 95-112.
[PMID: 2690101] 
[12] 
Reisberg B, Torossian C, Shulman MB, et al. Two year outcomes, cognitive and behavioral markers of decline in healthy, cognitively normal older persons with global deterioration scale stage 2 (subjective cognitive decline with impairment). J Alzheimers Dis  2019; 67(2): 685-705.
[http://dx.doi.org/10.3233/JAD-180341] [PMID: 30689585] 
[13] 
Sheikh F, Ismail Z, Mortby ME, et al. Prevalence of mild behavioral impairment in mild cognitive impairment and subjective cognitive decline, and its association with caregiver burden. Int Psychogeriatr  2018; 30(2): 233-44.
[http://dx.doi.org/10.1017/S104161021700151X] [PMID: 28879833] 
[14] 
Slot RER, Verfaillie SCJ, Overbeek JM, et al. Subjective cognitive impairment cohort (science): Study design and first results. Alzheimers Res Ther  2018; 10(1): 76.
[http://dx.doi.org/10.1186/s13195-018-0390-y] [PMID: 30081935] 
[15] 
Feldman H, Scheltens P, Scarpini E. Behavioral symptoms in mild cognitive impairment. Neurology  2004; 62(7): 1199-201.
[http://dx.doi.org/10.1212/01.WNL.0000118301.92105.EE] [PMID: 15079026] 
[16] 
Forsell Y, Palmer K, Fratiglioni L. Psychiatric symptoms/syndromes in elderly persons with mild cognitive impairment. Data from a cross-sectional study. Acta Neurol Scand Suppl  2003; 179: 25-8.
[http://dx.doi.org/10.1034/j.1600-0404.107.s179.4.x] [PMID: 12603247] 
[17] 
Geda YE, Smith GE, Knopman DS, et al. De novo genesis of neuropsychiatric symptoms in mild cognitive impairment (MCI). Int Psychogeriatr  2004; 16(1): 51-60.
[http://dx.doi.org/10.1017/S1041610204000067] [PMID: 15190996] 
[18] 
Lopez OL, Becker JT, Sweet RA. Non-cognitive symptoms in mild cognitive impairment subjects. Neurocase  2005; 11(1): 65-71.
[http://dx.doi.org/10.1080/13554790490896893] [PMID: 15804926] 
[19] 
Lyketsos CG, Lopez O, Jones B, Fitzpatrick AL, Breitner J, DeKosky S. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: Results from the cardiovascular health study. JAMA  2002; 288(12): 1475-83.
[http://dx.doi.org/10.1001/jama.288.12.1475] [PMID: 12243634] 
[20] 
Rosenberg PB, Mielke MM, Appleby B, Oh E, Leoutsakos JM, Lyketsos CG. Neuropsychiatric symptoms in MCI subtypes: The importance of executive dysfunction. Int J Geriatr Psychiatry  2011; 26(4): 364-72.
[http://dx.doi.org/10.1002/gps.2535] [PMID: 20845402] 
[21] 
Siafarikas N, Selbaek G, Fladby T, Šaltytė Benth J, Auning E, Aarsland D. Frequency and subgroups of neuropsychiatric symptoms in mild cognitive impairment and different stages of dementia in Alzheimer’s disease. Int Psychogeriatr  2018; 30(1): 103-13.
[http://dx.doi.org/10.1017/S1041610217001879] [PMID: 28927477] 
[22] 
Hwang TJ, Masterman DL, Ortiz F, Fairbanks LA, Cummings JL. Mild cognitive impairment is associated with characteristic neuropsychiatric symptoms. Alzheimer Dis Assoc Disord  2004; 18(1): 17-21.
[http://dx.doi.org/10.1097/00002093-200401000-00004] [PMID: 15195459] 
[23] 
Robert PH, Berr C, Volteau M, et al. Neuropsychological performance in mild cognitive impairment with and without apathy. Dement Geriatr Cogn Disord  2006; 21(3): 192-7.
[http://dx.doi.org/10.1159/000090766] [PMID: 16424666] 
[24] 
Aalten P, Verhey FR, Boziki M, et al. Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: Part I. Dement Geriatr Cogn Disord  2007; 24(6): 457-63.
[http://dx.doi.org/10.1159/000110738] [PMID: 17986816] 
[25] 
Fernández M, Gobartt AL, Balañá M, Group CS. Behavioural symptoms in patients with Alzheimer’s disease and their association with cognitive impairment. BMC Neurol  2010; 10: 87.
[http://dx.doi.org/10.1186/1471-2377-10-87] [PMID: 20920205] 
[26] 
Fernández Martínez M, Castro Flores J, Pérez de las Heras S, Mandaluniz Lekumberri A, Gordejuela Menocal M, Zarranz Imirizaldu JJ. Prevalence of neuropsychiatric symptoms in elderly patients with dementia in Mungialde County (Basque Country, Spain). Dement Geriatr Cogn Disord  2008; 25(2): 103-8.
[http://dx.doi.org/10.1159/000112215] [PMID: 18063866] 
[27] 
Karttunen K, Karppi P, Hiltunen A, et al. Neuropsychiatric symptoms and quality of life in patients with very mild and mild Alzheimer’s disease. Int J Geriatr Psychiatry  2011; 26(5): 473-82.
[http://dx.doi.org/10.1002/gps.2550] [PMID: 21445998] 
[28] 
Lyketsos CG, Sheppard JM, Steinberg M, et al. Neuropsychiatric disturbance in Alzheimer’s disease clusters into three groups: The Cache County study. Int J Geriatr Psychiatry  2001; 16(11): 1043-53.
[http://dx.doi.org/10.1002/gps.448] [PMID: 11746650] 
[29] 
Tatsch MF, Bottino CM, Azevedo D, et al. Neuropsychiatric symptoms in Alzheimer disease and cognitively impaired, nondemented elderly from a community-based sample in Brazil: Prevalence and relationship with dementia severity. Am J Geriatr Psychiatry  2006; 14(5): 438-45.
[http://dx.doi.org/10.1097/01.JGP.0000218218.47279.db] [PMID: 16670248] 
[30] 
Teri L, Ferretti LE, Gibbons LE, et al. Anxiety of Alzheimer’s disease: Prevalence, and comorbidity. J Gerontol A Biol Sci Med Sci  1999; 54(7): M348-52.
[http://dx.doi.org/10.1093/gerona/54.7.M348] [PMID: 10462166] 
[31] 
Treiber KA, Lyketsos CG, Corcoran C, et al. Vascular factors and risk for neuropsychiatric symptoms in Alzheimer’s disease: The Cache County Study. Int Psychogeriatr  2008; 20(3): 538-53.
[http://dx.doi.org/10.1017/S1041610208006704] [PMID: 18289451] 
[32] 
van Vliet D, de Vugt ME, Aalten P, et al. Prevalence of neuropsychiatric symptoms in young-onset compared to late-onset alzheimer’s disease - part 1: Findings of the two-year longitudinal NeedYD-study. Dement Geriatr Cogn Disord  2012; 34(5-6): 319-27.
[http://dx.doi.org/10.1159/000342824] [PMID: 23208452] 
[33] 
Cheng ST, Kwok T, Lam LC. Neuropsychiatric symptom clusters of Alzheimer’s disease in Hong Kong Chinese: Prevalence and confirmatory factor analysis of the Neuropsychiatric Inventory. Int Psychogeriatr  2012; 24(9): 1465-73.
[http://dx.doi.org/10.1017/S1041610212000609] [PMID: 22717370] 
[34] 
Chiu MJ, Chen TF, Yip PK, Hua MS, Tang LY. Behavioral and psychologic symptoms in different types of dementia. J Formos Med Assoc  2006; 105(7): 556-62.
[http://dx.doi.org/10.1016/S0929-6646(09)60150-9] [PMID: 16877235] 
[35] 
Chow TW, Liu CK, Fuh JL, et al. Neuropsychiatric symptoms of Alzheimer’s disease differ in Chinese and American patients. Int J Geriatr Psychiatry  2002; 17(1): 22-8.
[http://dx.doi.org/10.1002/gps.509] [PMID: 11802226] 
[36] 
D’Onofrio G, Sancarlo D, Panza F, et al. Neuropsychiatric symptoms and functional status in Alzheimer’s disease and vascular dementia patients. Curr Alzheimer Res  2012; 9(6): 759-71.
[http://dx.doi.org/10.2174/156720512801322582] [PMID: 22715983] 
[37] 
Fuh JL, Wang SJ, Cummings JL. Neuropsychiatric profiles in patients with Alzheimer’s disease and vascular dementia. J Neurol Neurosurg Psychiatry  2005; 76(10): 1337-41.
[http://dx.doi.org/10.1136/jnnp.2004.056408] [PMID: 16170072] 
[38] 
Hart DJ, Craig D, Compton SA, et al. A retrospective study of the behavioural and psychological symptoms of mid and late phase Alzheimer’s disease. Int J Geriatr Psychiatry  2003; 18(11): 1037-42.
[http://dx.doi.org/10.1002/gps.1013] [PMID: 14618556] 
[39] 
Haupt M, Kurz A, Jänner M. A 2-year follow-up of behavioural and psychological symptoms in Alzheimer’s disease. Dement Geriatr Cogn Disord  2000; 11(3): 147-52.
[http://dx.doi.org/10.1159/000017228] [PMID: 10765045] 
[40] 
Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer’s disease. Neurology  1996; 46(1): 130-5.
[http://dx.doi.org/10.1212/WNL.46.1.130] [PMID: 8559361] 
[41] 
Mirakhur A, Craig D, Hart DJ, McLlroy SP, Passmore AP. Behavioural and psychological syndromes in Alzheimer’s disease. Int J Geriatr Psychiatry  2004; 19(11): 1035-9.
[http://dx.doi.org/10.1002/gps.1203] [PMID: 15481075] 
[42] 
Steffens DC, Maytan M, Helms MJ, Plassman BL. Prevalence and clinical correlates of neuropsychiatric symptoms in dementia. Am J Alzheimers Dis Other Demen  2005; 20(6): 367-73.
[http://dx.doi.org/10.1177/153331750502000611] [PMID: 16396442] 
[43] 
Devanand DP, Pradhaban G, Liu X, et al. Hippocampal and entorhinal atrophy in mild cognitive impairment: Prediction of Alzheimer disease. Neurology  2007; 68(11): 828-36.
[http://dx.doi.org/10.1212/01.wnl.0000256697.20968.d7] [PMID: 17353470] 
[44] 
Jack CR Jr, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer’s disease: An updated hypothetical model of dynamic biomarkers. Lancet Neurol  2013; 12(2): 207-16.
[http://dx.doi.org/10.1016/S1474-4422(12)70291-0] [PMID: 23332364] 
[45] 
Pink A, Przybelski SA, Krell-Roesch J, et al. Cortical thickness and anxiety symptoms among cognitively normal elderly persons: The mayo clinic study of aging. J Neuropsychiatry Clin Neurosci  2017; 29(1): 60-6.
[http://dx.doi.org/10.1176/appi.neuropsych.15100378] [PMID: 27578447] 
[46] 
Bonthius DJ, Solodkin A, Van Hoesen GW. Pathology of the insular cortex in Alzheimer disease depends on cortical architecture. J Neuropathol Exp Neurol  2005; 64(10): 910-22.
[http://dx.doi.org/10.1097/01.jnen.0000182983.87106.d1] [PMID: 16215463] 
[47] 
Sun Y, Wang X, Wang Y, et al. Anxiety correlates with cortical surface area in subjective cognitive decline: APOE ε4 carriers versus APOE ε4 non-carriers. Alzheimers Res Ther  2019; 11(1): 50.
[http://dx.doi.org/10.1186/s13195-019-0505-0] [PMID: 31159873] 
[48] 
Mah L, Binns MA, Steffens DC. Anxiety symptoms in amnestic mild cognitive impairment are associated with medial temporal atrophy and predict conversion to Alzheimer disease. Am J Geriatr Psychiatry  2015; 23(5): 466-76.
[http://dx.doi.org/10.1016/j.jagp.2014.10.005] [PMID: 25500120] 
[49] 
Staekenborg SS, Gillissen F, Romkes R, et al. Behavioural and psychological symptoms are not related to white matter hyperintensities and medial temporal lobe atrophy in Alzheimer’s disease. Int J Geriatr Psychiatry  2008; 23(4): 387-92.
[http://dx.doi.org/10.1002/gps.1891] [PMID: 17907266] 
[50] 
Berlow YA, Wells WM, Ellison JM, Sung YH, Renshaw PF, Harper DG. Neuropsychiatric correlates of white matter hyperintensities in Alzheimer’s disease. Int J Geriatr Psychiatry  2010; 25(8): 780-8.
[http://dx.doi.org/10.1002/gps.2418] [PMID: 19946864] 
[51] 
García-Alberca JM, Florido M, Cáceres M, Sánchez-Toro A, Lara JP, García-Casares N. Medial temporal lobe atrophy is independently associated with behavioural and psychological symptoms in Alzheimer’s disease. Psychogeriatrics  2019; 19(1): 46-54.
[http://dx.doi.org/10.1111/psyg.12363] [PMID: 30084177] 
[52] 
García-Alberca JM, Mendoza S, Gris E, Royo JL, Cruz-Gamero JM, García-Casares N. White matter lesions and temporal atrophy are associated with cognitive and neuropsychiatric symptoms in patients with hypertension and Alzheimer’s disease. Int J Geriatr Psychiatry  2020; 35(11): 1292-300.
[http://dx.doi.org/10.1002/gps.5366] [PMID: 32584440] 
[53] 
Horínek D, Petrovický P, Hort J, et al. Amygdalar volume and psychiatric symptoms in Alzheimer’s disease: An MRI analysis. Acta Neurol Scand  2006; 113(1): 40-5.
[http://dx.doi.org/10.1111/j.1600-0404.2006.00540.x] [PMID: 16367898] 
[54] 
Poulin SP, Dautoff R, Morris JC, Barrett LF, Dickerson BC. Amygdala atrophy is prominent in early Alzheimer’s disease and relates to symptom severity. Psychiatry Res  2011; 194(1): 7-13.
[http://dx.doi.org/10.1016/j.pscychresns.2011.06.014] [PMID: 21920712] 
[55] 
Tovote P, Fadok JP, Lüthi A. Neuronal circuits for fear and anxiety. Nat Rev Neurosci  2015; 16(6): 317-31.
[http://dx.doi.org/10.1038/nrn3945] [PMID: 25991441] 
[56] 
Mosconi L, Tsui WH, Herholz K, et al. Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer’s disease, and other dementias. J Nucl Med  2008; 49(3): 390-8.
[http://dx.doi.org/10.2967/jnumed.107.045385] [PMID: 18287270] 
[57] 
Krell-Roesch J, Ruider H, Lowe VJ, et al. FDG-PET and neuropsychiatric symptoms among cognitively normal elderly persons: The mayo clinic study of aging. J Alzheimers Dis  2016; 53(4): 1609-16.
[http://dx.doi.org/10.3233/JAD-160326] [PMID: 27447426] 
[58] 
Krell-Roesch J, Syrjanen JA, Vassilaki M, et al. Brain regional glucose metabolism, neuropsychiatric symptoms, and the risk of incident mild cognitive impairment: The Mayo clinic study of aging. Am J Geriatr Psychiatry  2021; 29(2): 179-91.
[PMID: 32646634] 
[59] 
Hashimoto H, Monserratt L, Nguyen P, et al. Anxiety and regional cortical glucose metabolism in patients with Alzheimer’s disease. J Neuropsychiatry Clin Neurosci  2006; 18(4): 521-8.
[http://dx.doi.org/10.1176/jnp.2006.18.4.521] [PMID: 17135378] 
[60] 
Sultzer DL, Mahler ME, Mandelkern MA, et al. The relationship between psychiatric symptoms and regional cortical metabolism in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci  1995; 7(4): 476-84.
[http://dx.doi.org/10.1176/jnp.7.4.476] [PMID: 8555751] 
[61] 
Pietrzak RH, Lim YY, Neumeister A, et al. Amyloid-β, anxiety, and cognitive decline in preclinical Alzheimer disease: A multicenter, prospective cohort study. JAMA Psychiatry  2015; 72(3): 284-91.
[http://dx.doi.org/10.1001/jamapsychiatry.2014.2476] [PMID: 25629787] 
[62] 
Hanseeuw BJ, Jonas V, Jackson J, et al. Association of anxiety with subcortical amyloidosis in cognitively normal older adults. Mol Psychiatry  2020; 25(10): 2599-607.
[http://dx.doi.org/10.1038/s41380-018-0214-2] [PMID: 30116029] 
[63] 
Krell-Roesch J, Lowe VJ, Neureiter J, et al. Depressive and anxiety symptoms and cortical amyloid deposition among cognitively normal elderly persons: The Mayo Clinic Study of Aging. Int Psychogeriatr  2018; 30(2): 245-51.
[http://dx.doi.org/10.1017/S1041610217002368] [PMID: 29198244] 
[64] 
Bensamoun D, Guignard R, Furst AJ, et al. Associations between neuropsychiatric symptoms and cerebral amyloid deposition in cognitively impaired elderly people. J Alzheimers Dis  2016; 49(2): 387-98.
[http://dx.doi.org/10.3233/JAD-150181] [PMID: 26484900] 
[65] 
Babulal GM, Ghoshal N, Head D, et al. Mood changes in cognitively normal older adults are linked to alzheimer disease biomarker levels. Am J Geriatr Psychiatry  2016; 24(11): 1095-104.
[http://dx.doi.org/10.1016/j.jagp.2016.04.004] [PMID: 27426238] 
[66] 
Lavretsky H, Siddarth P, Kepe V, et al. Depression and anxiety symptoms are associated with cerebral FDDNP-PET binding in middle-aged and older nondemented adults. Am J Geriatr Psychiatry  2009; 17(6): 493-502.
[http://dx.doi.org/10.1097/JGP.0b013e3181953b82] [PMID: 19472439] 
[67] 
Krell-Roesch J, Vassilaki M, Mielke MM, et al. Cortical β-amyloid burden, neuropsychiatric symptoms, and cognitive status: The Mayo Clinic Study of Aging. Transl Psychiatry  2019; 9(1): 123.
[http://dx.doi.org/10.1038/s41398-019-0456-z] [PMID: 30923322] 
[68] 
Johansson M, Stomrud E, Lindberg O, et al. Apathy and anxiety are early markers of Alzheimer’s disease. Neurobiol Aging  2020; 85: 74-82.
[http://dx.doi.org/10.1016/j.neurobiolaging.2019.10.008] [PMID: 31735378] 
[69] 
Ramakers IH, Verhey FR, Scheltens P, et al. Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment. Psychol Med  2013; 43(5): 911-20.
[http://dx.doi.org/10.1017/S0033291712001870] [PMID: 22954311] 
[70] 
Goukasian N, Hwang KS, Romero T, et al. Association of brain amyloidosis with the incidence and frequency of neuropsychiatric symptoms in ADNI: A multisite observational cohort study. BMJ Open  2019; 9(12)e031947
[http://dx.doi.org/10.1136/bmjopen-2019-031947] [PMID: 31857304] 
[71] 
Nelson PT, Alafuzoff I, Bigio EH, et al. Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature. J Neuropathol Exp Neurol  2012; 71(5): 362-81.
[http://dx.doi.org/10.1097/NEN.0b013e31825018f7] [PMID: 22487856] 
[72] 
Förstl H, Burns A, Luthert P, Cairns N, Lantos P, Levy R. Clinical and neuropathological correlates of depression in Alzheimer’s disease. Psychol Med  1992; 22(4): 877-84.
[http://dx.doi.org/10.1017/S0033291700038459] [PMID: 1488485] 
[73] 
Guadagna S, Esiri MM, Williams RJ, Francis PT. Tau phosphorylation in human brain: Relationship to behavioral disturbance in dementia. Neurobiol Aging  2012; 33(12): 2798-806.
[http://dx.doi.org/10.1016/j.neurobiolaging.2012.01.015] [PMID: 22382406] 
[74] 
Marshall GA, Fairbanks LA, Tekin S, Vinters HV, Cummings JL. Neuropathologic correlates of apathy in Alzheimer’s disease. Dement Geriatr Cogn Disord  2006; 21(3): 144-7.
[http://dx.doi.org/10.1159/000090674] [PMID: 16391476] 
[75] 
Rapp MA, Schnaider-Beeri M, Grossman HT, et al. Increased hippocampal plaques and tangles in patients with Alzheimer disease with a lifetime history of major depression. Arch Gen Psychiatry  2006; 63(2): 161-7.
[http://dx.doi.org/10.1001/archpsyc.63.2.161] [PMID: 16461859] 
[76] 
Tekin S, Mega MS, Masterman DM, et al. Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease. Ann Neurol  2001; 49(3): 355-61.
[http://dx.doi.org/10.1002/ana.72] [PMID: 11261510] 
[77] 
Wilson RS, Nag S, Boyle PA, et al. Brainstem aminergic nuclei and late-life depressive symptoms. JAMA Psychiatry  2013; 70(12): 1320-8.
[http://dx.doi.org/10.1001/jamapsychiatry.2013.2224] [PMID: 24132763] 
[78] 
Ehrenberg AJ, Suemoto CK, França Resende EP, et al. Neuropathologic correlates of psychiatric symptoms in Alzheimer’s disease. J Alzheimers Dis  2018; 66(1): 115-26.
[http://dx.doi.org/10.3233/JAD-180688] [PMID: 30223398] 
[79] 
Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol  1991; 82(4): 239-59.
[http://dx.doi.org/10.1007/BF00308809] [PMID: 1759558] 
[80] 
Bennett DA, Schneider JA, Bienias JL, Evans DA, Wilson RS. Mild cognitive impairment is related to Alzheimer disease pathology and cerebral infarctions. Neurology  2005; 64(5): 834-41.
[http://dx.doi.org/10.1212/01.WNL.0000152982.47274.9E] [PMID: 15753419] 
[81] 
Ballard C, Neill D, O’Brien J, McKeith IG, Ince P, Perry R. Anxiety, depression and psychosis in vascular dementia: Prevalence and associations. J Affect Disord  2000; 59(2): 97-106.
[http://dx.doi.org/10.1016/S0165-0327(99)00057-9] [PMID: 10837878] 
[82] 
Segers K, Benoit F, Meyts JM, Surquin M. Anxiety symptoms are quantitatively and qualitatively different in dementia with Lewy bodies than in Alzheimer’s disease in the years preceding clinical diagnosis. Psychogeriatrics  2020; 20(3): 242-6.
[http://dx.doi.org/10.1111/psyg.12490] [PMID: 31782249] 
[83] 
Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. JAMA  1997; 278(16): 1349-56.
[http://dx.doi.org/10.1001/jama.1997.03550160069041] [PMID: 9343467] 
[84] 
Holmes SE, Esterlis I, Mazure CM, et al. β-amyloid, apoe and bdnf genotype, and depressive and anxiety symptoms in cognitively normal older women and men. Am J Geriatr Psychiatry  2016; 24(12): 1191-5.
[http://dx.doi.org/10.1016/j.jagp.2016.08.007] [PMID: 
                       27742526] 
[85] 
Robertson J, Curley J, Kaye J, Quinn J, Pfankuch T, Raber J. apoE isoforms and measures of anxiety in probable AD patients and Apoe-/- mice. Neurobiol Aging  2005; 26(5): 637-43.
[http://dx.doi.org/10.1016/j.neurobiolaging.2004.06.003] [PMID: 15708438] 
[86] 
Michels A, Multhammer M, Zintl M, Mendoza MC, Klünemann HH. Association of apolipoprotein E ε4 (ApoE ε4) homozygosity with psychiatric behavioral symptoms. J Alzheimers Dis  2012; 28(1): 25-32.
[http://dx.doi.org/10.3233/JAD-2011-110554] [PMID: 22246233] 
[87] 
Mosca A, Sperduti S, Pop V, et al. Influence of apoe and rnf219 on behavioral and cognitive features of female patients affected by mild cognitive impairment or alzheimer’s disease. Front Aging Neurosci  2018; 10: 92.
[http://dx.doi.org/10.3389/fnagi.2018.00092] [PMID: 29755337] 
[88] 
Senanarong V, An SSA, Vo Van G, Limwongse C, Bagyinszky E, Kim S. Pathogenic psen1 glu184gly mutation in a family from thailand with probable autosomal dominant early onset alzheimer’s disease. Diagnostics (Basel)  2020; 10(3)E135
[http://dx.doi.org/10.3390/diagnostics10030135] [PMID: 32121568] 
[89] 
Sinning M, van Rooyen JP, Venegas-Francke P, Vásquez C, Behrens MI, Ramírez A. Clinical and genetic analysis of a chilean family with early-onset autosomal dominant Alzheimer’s disease. J Alzheimers Dis  2010; 21(3): 757-61.
[http://dx.doi.org/10.3233/JAD-2010-100135] [PMID: 20571222] 
[90] 
Swearer JM, O’Donnell BF, Parker M, Kane KJ, Drachman DA. Psychological features in persons at risk for familial Alzheimer’s disease. Am J Alzheimers Dis Other Demen  2001; 16(3): 157-62.
[http://dx.doi.org/10.1177/153331750101600311] [PMID: 11398564] 
[91] 
Ringman JM, Liang LJ, Zhou Y, et al. Early behavioural changes in familial alzheimer’s disease in the dominantly inherited alzheimer network. Brain  2015; 138(Pt 4): 1036-45.
[http://dx.doi.org/10.1093/brain/awv004] [PMID: 25688083] 
[92] 
Donovan NJ, Amariglio RE, Zoller AS, et al. Subjective cognitive concerns and neuropsychiatric predictors of progression to the early clinical stages of Alzheimer disease. Am J Geriatr Psychiatry  2014; 22(12): 1642-51.
[http://dx.doi.org/10.1016/j.jagp.2014.02.007] [PMID: 24698445] 
[93] 
Sinoff G, Werner P. Anxiety disorder and accompanying subjective memory loss in the elderly as a predictor of future cognitive decline. Int J Geriatr Psychiatry  2003; 18(10): 951-9.
[http://dx.doi.org/10.1002/gps.1004] [PMID: 14533128] 
[94] 
Snitz BE, Wang T, Cloonan YK, et al. Risk of progression from subjective cognitive decline to mild cognitive impairment: The role of study setting. Alzheimers Dement  2018; 14(6): 734-42.
[http://dx.doi.org/10.1016/j.jalz.2017.12.003] [PMID: 29352855] 
[95] 
Liew TM. Subjective cognitive decline, anxiety symptoms, and the risk of mild cognitive impairment and dementia. Alzheimers Res Ther  2020; 12(1): 107.
[http://dx.doi.org/10.1186/s13195-020-00673-8] [PMID: 32917264] 
[96] 
Palmer K, Berger AK, Monastero R, Winblad B, Bäckman L, Fratiglioni L. Predictors of progression from mild cognitive impairment to Alzheimer disease. Neurology  2007; 68(19): 1596-602.
[http://dx.doi.org/10.1212/01.wnl.0000260968.92345.3f] [PMID: 17485646] 
[97] 
Wadsworth LP, Lorius N, Donovan NJ, et al. Neuropsychiatric symptoms and global functional impairment along the Alzheimer’s continuum. Dement Geriatr Cogn Disord  2012; 34(2): 96-111.
[http://dx.doi.org/10.1159/000342119] [PMID: 22922821] 
[98] 
Rosenberg PB, Mielke MM, Appleby BS, Oh ES, Geda YE, Lyketsos CG. The association of neuropsychiatric symptoms in MCI with incident dementia and Alzheimer disease. Am J Geriatr Psychiatry  2013; 21(7): 685-95.
[http://dx.doi.org/10.1016/j.jagp.2013.01.006] [PMID: 23567400] 
[99] 
Somme J, Fernández-Martínez M, Molano A, Zarranz JJ. Neuropsychiatric symptoms in amnestic mild cognitive impairment: Increased risk and faster progression to dementia. Curr Alzheimer Res  2013; 10(1): 86-94.
[PMID: 23016837] 
[100] 
Ramakers IH, Visser PJ, Aalten P, Kester A, Jolles J, Verhey FR. Affective symptoms as predictors of Alzheimer’s disease in subjects with mild cognitive impairment: A 10-year follow-up study. Psychol Med  2010; 40(7): 1193-201.
[http://dx.doi.org/10.1017/S0033291709991577] [PMID: 19903364] 
[101] 
Devier DJ, Pelton GH, Tabert MH, et al. The impact of anxiety on conversion from mild cognitive impairment to Alzheimer’s disease. Int J Geriatr Psychiatry  2009; 24(12): 1335-42.
[http://dx.doi.org/10.1002/gps.2263] [PMID: 19319929] 
[102] 
Liu HC, Wang PN, Wang HC, et al. Conversion to dementia from questionable dementia in an ethnic Chinese population. J Geriatr Psychiatry Neurol  2007; 20(2): 76-83.
[http://dx.doi.org/10.1177/0891988706298626] [PMID: 17548776] 
[103] 
Bah TM, Goodman J, Iliff JJ. Sleep as a therapeutic target in the aging brain. Neurotherapeutics  2019; 16(3): 554-68.
[http://dx.doi.org/10.1007/s13311-019-00769-6] [PMID: 31376067] 
[104] 
Cox RC, Olatunji BO. A systematic review of sleep disturbance in anxiety and related disorders. J Anxiety Disord  2016; 37: 104-29.
[http://dx.doi.org/10.1016/j.janxdis.2015.12.001] [PMID: 26745517] 
[105] 
Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT. Inflammation as a central mechanism in Alzheimer’s disease. Alzheimers Dement (N Y)  2018; 4: 575-90.
[http://dx.doi.org/10.1016/j.trci.2018.06.014] [PMID: 30406177] 
[106] 
Furtado M, Katzman MA. Neuroinflammatory pathways in anxiety, posttraumatic stress, and obsessive compulsive disorders. Psychiatry Res  2015; 229(1-2): 37-48.
[http://dx.doi.org/10.1016/j.psychres.2015.05.036] [PMID: 26296951] 
[107] 
Arborelius L, Owens MJ, Plotsky PM, Nemeroff CB. The role of corticotropin-releasing factor in depression and anxiety disorders. J Endocrinol  1999; 160(1): 1-12.
[http://dx.doi.org/10.1677/joe.0.1600001] [PMID: 9854171] 
[108] 
Ouanes S, Popp J. High cortisol and the risk of dementia and alzheimer’s disease: A review of the literature. Front Aging Neurosci  2019; 11: 43.
[http://dx.doi.org/10.3389/fnagi.2019.00043] [PMID: 30881301] 
[109] 
Wuwongse S, Chang RC, Law AC. The putative neurodegenerative links between depression and Alzheimer’s disease. Prog Neurobiol  2010; 91(4): 362-75.
[http://dx.doi.org/10.1016/j.pneurobio.2010.04.005] [PMID: 20441786] 
[110] 
Leonpacher AK, Peters ME, Drye LT, et al. Effects of citalopram on neuropsychiatric symptoms in alzheimer’s dementia: Evidence from the citad study. Am J Psychiatry  2016; 173(5): 473-80.
[http://dx.doi.org/10.1176/appi.ajp.2016.15020248] [PMID: 27032628] 
[111] 
Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. Br J Psychiatry  1990; 157: 894-901.
[http://dx.doi.org/10.1192/bjp.157.6.894] [PMID: 1705151] 
[112] 
Raji MA, Brady SR. Mirtazapine for treatment of depression and comorbidities in Alzheimer disease. Ann Pharmacother  2001; 35(9): 1024-7.
[http://dx.doi.org/10.1345/aph.10371] [PMID: 11573849] 
[113] 
Lebert F, Pasquier F, Petit H. Behavioral effects of trazodone in Alzheimer’s disease. J Clin Psychiatry  1994; 55(12): 536-8.
[PMID: 7814348] 
[114] 
Gauthier S, Feldman H, Hecker J, et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer’s disease. Int Psychogeriatr  2002; 14(4): 389-404.
[http://dx.doi.org/10.1017/S104161020200858X] [PMID: 12670060] 
[115] 
Savaskan E, Schnitzler C, Schröder C, Cajochen C, Müller-Spahn F, Wirz-Justice A. Treatment of behavioural, cognitive and circadian rest-activity cycle disturbances in Alzheimer’s disease: Haloperidol vs. quetiapine. Int J Neuropsychopharmacol  2006; 9(5): 507-16.
[http://dx.doi.org/10.1017/S1461145705006036] [PMID: 16316485] 
[116] 
Streim JE, Porsteinsson AP, Breder CD, et al. A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease. Am J Geriatr Psychiatry  2008; 16(7): 537-50.
[http://dx.doi.org/10.1097/JGP.0b013e318165db77] [PMID: 18591574] 
[117] 
Burke SL, O’Driscoll J, Alcide A, Li T. Moderating risk of Alzheimer’s disease through the use of anxiolytic agents. Int J Geriatr Psychiatry  2017; 32(12): 1312-21.
[http://dx.doi.org/10.1002/gps.4614] [PMID: 27805724] 
Rights & Permissions Print Cite
Article Metrics
33
1
Journal Information
For Authors
For Editors
For Reviewers
Explore Articles
Open Access
Open Access Articles
For Visitors
DOI https://dx.doi.org/10.2174/1567205018666210823095603	Print ISSN 1567-2050
Publisher Name Bentham Science Publisher	Online ISSN 1875-5828
当代阿耳茨海默病研究

焦虑与阿尔茨海默病的关系：叙事评论

摘要

当代阿耳茨海默病研究

焦虑与阿尔茨海默病的关系：叙事评论

摘要 Play Pause

Related Journals

Related Books

摘要
